Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 26,331

Document Document Title
WO/2020/189540A1
The present invention provides a method for efficiently preparing various optically active aromatic amino acid derivatives by performing a reaction, in the presence of a catalyst, on a specific ester compound by using an aromatic halide ...  
WO/2020/188437A1
The present invention relates to compounds with a 5-(2-nitroethyI)-2,4,6- triaminopyrimidine structure, derivatised at the 1 position on the ethylene chain with heteroaromatic or phenyl-benzylether rings. The invention also relates to th...  
WO/2020/186812A1
The present application relates to the technical field of biomedicine, and specifically discloses a multi-target kinase inhibitor and a pharmaceutical composition comprising the multi-target kinase inhibitor, and further discloses a prep...  
WO/2020/184906A1
The present invention relates to a novel organic light emitting compound and an organic electroluminescent device using same and, more particularly, to a compound having excellent thermal stability, electrochemical stability, light-emitt...  
WO/2020/186025A1
The present invention is related to the discovery of a combination therapy for the treatment or prevention of cytomegalovirus infection.in humans and other mammals, comprising the administration of a synergistic therapeutic effective amo...  
WO/2020/181165A1
Provided herein are compounds of formula (I), compositions comprising the compounds and method of treating various diseases with the compounds and compositions.  
WO/2020/127208A3
The present disclosure concerns the large-scale manufacture of pharmaceutical compounds, and novel intermediates for use in the manufacture. International Patent Application WO2011154737 discloses morpholine pyrimidines useful for treati...  
WO/2020/180005A1
The present specification relates to a binaphthalene compound represented by chemical formula 1 and an organic light emitting device comprising same.  
WO/2020/181283A1
The invention relates to carboxamide-pyrimidine derivatives of the general formula (I), or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases...  
WO/2020/180624A1
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function ...  
WO/2020/172932A1
Disclosed is a WDR5 protein-protein interaction inhibitor, containing a compound with a structure as shown in general formula (I). Experiments show that the inhibitor acts on the WDR5 protein and interacting proteins thereof, including, ...  
WO/2020/172664A1
Described herein are genetic recognition reagents that bind specifically to a target nucleic acid and comprise terminal left-handed PNA cooperative binding domains that enable concatenation of two or more of the recognition reagents when...  
WO/2020/168237A1
The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These no...  
WO/2020/165840A1
The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitr ile (compound I). The present disclosure further provides methods for treating ocular surface pain by administeri...  
WO/2020/163653A1
Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.  
WO/2020/051207A3
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...  
WO/2020/158841A1
The purpose of the present invention is to provide a novel compound capable of accelerating the proliferation of cells in cell culturing (particularly three-dimensional cell culturing). A hydrazide compound represented by formula (I) [wh...  
WO/2020/160493A2
Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions. Also provided herein are methods of preventing or delaying the onset of myopia in a subject in need thereof, ...  
WO/2020/155742A1
Disclosed in the present invention are a method for deriving aldehyde-based pyrimidine, a method for detecting 5-aldehyde cytosine, and a use of the aldehyde-based pyrimidine derivative. The present invention mixes aldehyde-based pyrimid...  
WO/2020/160202A1
Disclosed are compounds of Formula 1, including all stereoisomers, A-oxides, and salts thereof, wherein A is selected from and X, Q1, Q2, Q3, Q4, R, R1, R2, R3, R4 and n are as defined in the disclosure. Also disclosed are compositions c...  
WO/2020/160321A1
The present invention provides compounds and methods for treating MKP5 modulated disease. In certain embodiments, the MKP5 modulated disease is a fibrotic disease.  
WO/2020/157069A1
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...  
WO/2020/157474A1
The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of ...  
WO/2020/159343A1
The present invention relates to an amide derivative compound or a pharmaceutically acceptable salt thereof, which can be beneficially used in the treatment or prevention of Middle East Respiratory Syndrome (MERS). In addition, the prese...  
WO/2020/157463A1
Disulphide compounds of Formula (I) where Y is sulphuryl or sulphinyl Z is phenyl or substituted phenyl and the other variables are as defined in the claims; pharmaceutical compositions comprising these compounds and methods for making t...  
WO/2020/151605A1
The present invention discloses deuterated benzylaminopyrimidinedione derivatives, the use thereof and the pharmaceutical composition containing the same. They may be used for suppressing the activities of myosin. The present invention a...  
WO/2020/151687A1
Provided is an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by a general formula (I), or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivati...  
WO/2020/151686A1
Provided in the present invention are an N-heteroaryl sulfonamide derivative, the preparation and use thereof. The N-heteroaryl sulfonamide derivative is an N-heteroaryl sulfonamide compound shown in general formula (I) or general formul...  
WO/2020/121123A3
Described herein are cyclopentyl nucleoside analogs of Formula (I), pharmaceutical compositions that include one or more cyclopentyl nucleoside analogs and methods of using the same to treat HBV, HDV and/or HIV. (I)  
WO/2020/152361A1
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...  
WO/2020/150385A1
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-nega...  
WO/2020/148617A1
The present invention disclosed 3-substituted phenylamidine compounds of general formula (I), wherein R1, R2, R3, R4, R4a, R4b, A and E have the same meanings as defined in description. The present invention further discloses methods for...  
WO/2020/150372A1
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-nega...  
WO/2020/132603A3
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts or tautomers thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or prevent...  
WO/2020/060429A4
The present invention relates to 6-diamino-2- cyclopropylaminopyrimidine-5-carbonitrile (dicyclanil) dodecylbenzenesulfonate, a method of preparing dicyclanil dodecylbenzenesulfonate, antiparasitic, preferably larvicide compositions comp...  
WO/2020/150170A1
New deuterated analogs of elagolix are provided. The novel deuterated elagolix analogs differ from the only previously disclosed deuterated elagolix analogs in structure based on the exclusion of deuterium at certain sites in the compoun...  
WO/2020/076274A3
The present invention is related to unique caffeic acid phenethyl ester (CAPE) analogues, methods for preparation of said molecules, and the usage of said unique molecules in the preparation of a pharmaceutical composition that is to be ...  
WO/2020/086595A8
Disclosed herein are inhibitors of deubiquitinating (DUB) enzyme USP7 (Ubiquitin Specific Protease 7). Also provided are methods of treating a disease or disorder modulated by USP7.  
WO/2020/146819A1
Described herein are methods for treating ALK5-mediated disease including myelodysplastic syndrome (MDS), anemia and anemia of chronic disease. Also provided are methods of inhibiting ALK5.  
WO/2020/102901A8
Provided herein are synthetic compounds useful for inhibiting bacterial growth and uses thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium...  
WO/2020/142748A1
This document provides methods and materials for increasing TFEB polypeptide levels. For example, compounds (e.g., organic compounds) having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, f...  
WO/2020/142735A1
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating or preventing inappropriate activation of a type I interferon (IFN) response in a subject...  
WO/2020/139701A1
Inhibitors of androgen receptors that are thienopyrimidine derivatives corresponding to formula (I), and salts thereof, and associated compositions and methods of treatment:  
WO/2020/136130A1
The method relates to a process for preparing 4,6-dihydroxypyrimidine by reacting malonic acid esters of formula (II) with a formic acid derivative of formula (III) in the presence of an alkaline metal alcoholate of formula (I) at an ele...  
WO/2020/135765A1
The present invention relates to a compound and use of the compound in drug preparation, a pharmaceutical composition containing the compound, a drug carrier, and drug combined use. The compound is a compound represented by formula (I), ...  
WO/2020/134921A1
Provided by the present invention are an amino quinazolinone and amino isoquinolone derivatives. It is verified by numerous experiments that the compounds provided by the present invention have good inhibiting effects on PI3Kα and PI3K...  
WO/2020/127208A2
The present disclosure concerns the large-scale manufacture of pharmaceutical compounds, and novel intermediates for use in the manufacture. International Patent Application WO2011154737 discloses morpholine pyrimidines useful for treati...  
WO/2020/132633A1
The present disclosure provides methods of treating cancer in a patient determined to have a HER2 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib, in combination ...  
WO/2019/079599A8
An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.  
WO/2020/131597A1
The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxi...  

Matches 1 - 50 out of 26,331